Clinical Trial Search

Primary: New or Recurrent Disease Progression Events, as Defined, or Death. — 110; 119 Participants — p=0.47

Primary: HbA1c (Glycosylated Haemoglobin A1c) — 7.08; 7.64 Percent (%) glycosylated haemoglobin — p=0.0010

Primary: Number of Participants Who Achieved a Major Clinical Response (MCR), Partial Clinical Response (PCR), or Nonclinical Response (NCR) Defined by British Isles Lupus…

Primary: Sum of Pain Intensity at Rest-Baseline to 24 Hours (SPI24rest), 1 Gram IV Acetaminophen vs. Placebo. — 1793.3; 1845.3 units on a scale (in millimeters)

Primary: Weeks With Weekly Platelet Response — 0.0; 11.0 Weeks — p=<0.0001

Primary: Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE). — 77; 86; 26 Participants

Primary: Primary Outcome Measure is Reduction of Flexion Contracture of the Primary Joint. — 91.3; 0 % Joints

Primary: Number of Subjects With Treatment Success, Assessed Per the Investigator's Static Global Assessment — 58; 17 participants — p=0.016

Primary: Number of Subjects With Treatment Success, Assessed Per the Investigator's Static Global Assessment (ISGA) — 31; 8 particpants — p=0.058

Primary: Local Tolerability Was Analyzed in Terms of Worst Score Post-Baseline. — 4.23; 3.06; 3.25; 4.13 Scores on a scale

Primary: Total Exposure to Etanercept With Gaps — 2882.50 Participant-years

Primary: Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While in Study — 143; 130 Participants

Primary: Determination of Sunscreen Protection Factor (SPF) — 14.72; 15.00 Score on a scale

Primary: Percentage of Heavy Drinking Days Over the Treatment Period — 14.75; 10.23; 19.77 Percentage of days — p=0.0245

Primary: Change in Frequency of Headache Episodes — 12.3; 13.4; -5.2; -5.3 Headache Episodes